Morgan Stanley Maintains Overweight on Avalyn Pharma, Lowers Price Target to $53
Morgan Stanley analyst Judah Frommer maintains Avalyn Pharma (NASDAQ:AVLN) with a Overweight and lowers the price target from $57 to $53.
Last updated: 2026-11-19 07:41:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Avalyn Pharma Inc. (AVLN) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $27.80, with a market capitalization of $1.24B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $22.24 to $40.17. This page covers its latest market performance, valuation, price trends and company information.
$1.24B | |
$27.74 | |
$29.06 | |
$27.25 | |
$27.92 | |
355.84K | |
350.74K | |
-- | |
$40.17 | |
$22.24 | |
-- | |
2026-09-30 |
Avalyn Pharma Inc. (AVLN) last closed at $27.80 as of 2026-11-18 21:21:00, down 0.48% ($0.14) from the previous close of $27.92.
During the latest regular trading session, AVLN traded between $27.25 and $29.06, with a volume of 355.84K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Avalyn Pharma Inc. (AVLN) moved from $31.17 to $27.80, representing a decline of 10.83% ($3.38).
The stock traded between $27.04 and $31.87 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 459.20 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 31.0%
AVLN is currently trading at $27.80, placing it 31.0% of the way from its 52-week low of $22.24 to its 52-week high of $40.17. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Exchange | NASDAQ |
| Company Website |
Latest news related to Avalyn Pharma Inc. and AVLN stock.
Morgan Stanley analyst Judah Frommer maintains Avalyn Pharma (NASDAQ:AVLN) with a Overweight and lowers the price target from $57 to $53.
Avalyn Pharma (NASDAQ:AVLN) reported quarterly losses of $(0.67) per share which beat the analyst consensus estimate of $(0.75) by 10.67 percent. This is a 96.71 percent increase over losses of $(20.34) per share from
Eligible investors can buy real shares of Avalyn Pharma Inc. (AVLN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to AVLN, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between AVLN shares and USD.
AVLN Shares to USD
1.00 AVLN shares = 27.795 USD
Calculations are estimates based on the latest available price and are for reference only.